In a strategic development set to reshape cross-border healthcare trade between South Asia and Eurasia Nutrify Today, Pharma Eurasia, and Uzbekistan’s Ministry of Health formalise a structured Indo–CIS corridor, with…

In a strategic development set to reshape cross-border healthcare trade between South Asia and Eurasia

Nutrify Today, Pharma Eurasia, and Uzbekistan’s Ministry of Health formalise a structured Indo–CIS corridor, with Pharma Eurasia 2026 (Tashkent, 20–22 May) as the commercial execution platform.

In a strategic development set to reshape cross-border healthcare trade between South Asia and Eurasia, the Ministry of Health of the Republic of Uzbekistan has aligned with Nutrify Today and Pharma Eurasia to formalize a structured Indo–CIS pharmaceutical and nutraceutical corridor—positioning Uzbekistan as the region’s premier gateway to the Commonwealth of Independent States (CIS) and the wider Eurasian market.

The trilateral initiative integrates policy facilitation, global industry leadership, and a dedicated commercial exhibition platform—creating a scalable and compliance-driven trade architecture for Indian and global manufacturers seeking structured access into high-growth Eurasian markets.

The CIS dietary supplements market currently exceeds $5.8 billion annually, with the broader CIS + Eurasia nutraceutical opportunity estimated at $7–10 billion—and growing rapidly, driven by:

Rising adoption of preventive healthcare and condition-specific supplementation

Expansion of organised pharmacy and retail chains across Russia, Central Asia, and the Caucasus

Strengthening regulatory frameworks that favour compliant, quality-certified products

A growing middle class demanding vitamins, botanicals, and functional nutrition

For Indian pharmaceutical and nutraceutical exporters, this corridor represents one of the most structured and policy-backed market-entry opportunities available today.

Uzbekistan has rapidly transformed into a regional pharmaceutical and nutraceutical hub through targeted industrial policy, including:

Dedicated Pharma Parks and industrial clusters designed to attract FDI and contract manufacturing

Regulatory modernisation aligned with international compliance standards

Strategic geographic positioning between India, Russia, and Central Asia

Trade-focused institutional reforms and investment facilitation frameworks

Tashkent’s Pharma Park now offers foreign pharmaceutical and nutraceutical companies a structured pathway to establish a regional manufacturing or distribution presence—with government-backed institutional support.